Please check your internet connection and try again.
## Ticagrelor (Brilinta)
### Overview
Ticagrelor is an oral, direct-acting P2Y12 platelet inhibitor. It is a member of the cyclopentyltriazolopyrimidine (CPTP) class.
### Primary Indications
* Inhibition of thrombotic events (myocardial infarction, stroke, cardiovascular death) in patients with acute coronary syndrome (ACS).
* Prevention of thrombotic events in patients with a history of myocardial infarction (MI) and at least one additional risk factor for cardiovascular events.
### Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or as per local guidelines/protocol. In some cases, may be continued beyond 12 months.
* **Post-MI with Risk Factors:**
* **Maintenance Dose:** 60 mg orally twice daily.
### Pediatric Dosing
* The safety and efficacy of ticagrelor in pediatric patients have not been established.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. No dose adjustment necessary in mild to moderate hepatic impairment. Avoid in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment necessary for mild, moderate, or severe renal impairment.
### Contraindications
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any of its components.
### Adverse Effects
* **Major Bleeding:** The most significant adverse effect. Can occur in gastrointestinal, intracranial, or other sites. Risk is higher in patients with recent TIA or stroke.
* **Dyspnea:** Commonly reported, often transient.
* **Bradycardia:** Symptomatic bradycardia can occur.
* **Increased Creatinine:** Transient increases may be observed.
* **Ventricular pauses:** Can occur during Holter monitoring.
### Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Strong inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor levels, potentially increasing bleeding risk. Strong inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor levels, potentially reducing efficacy.
* **Strong CYP3A4 Substrates:** Ticagrelor is a moderate CYP3A4 inhibitor and can increase the exposure of drugs metabolized by CYP3A4 (e.g., simvastatin, atorvastatin). Maximize statin doses if co-administered with ticagrelor 90 mg twice daily; monitor for statin-related adverse effects. Limit co-administration with high-dose statins if taking ticagrelor 60 mg twice daily.
* **Aspirin:** Concomitant use with aspirin is recommended for ACS patients, but increases bleeding risk. Duration of dual antiplatelet therapy (DAPT) should be individualized.
* **Other Antithrombotics:** Concomitant use with other anticoagulants or antiplatelet agents increases bleeding risk.
### Monitoring
* Monitor for signs and symptoms of bleeding.
* Assess for dyspnea.
* Monitor renal function and electrolytes periodically.
* For patients on ticagrelor 90 mg twice daily with a high-potency statin, consider monitoring for statin-related adverse effects.
### Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel.
* Dosing for ACS (180 mg load, then 90 mg BID) differs significantly from post-MI with risk factors (60 mg BID). Ensure correct indication and dose.
* DAPT duration is a critical decision, balancing ischemic and bleeding risk. Consult local protocols and patient-specific factors.
* Discontinuation of ticagrelor can increase the risk of thrombotic events. Reassess the risk/benefit of continuing therapy if discontinuation is considered, especially in patients with ACS.
* The 180 mg loading dose should be administered as soon as possible after ACS diagnosis.
***
*Disclaimer: This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the official prescribing information and relevant clinical guidelines for the most current and comprehensive drug information.*
